Cardiac Resynchronization Therapy News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.First Experience With Completely Leadless CRT First Experience With Completely Leadless CRT
Investigators report a small series of patients treated with leadless cardiac resynchronization therapy, showing feasibility and increased LV function at 6 months.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 28, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news
Updated ACC/AHA Heart Failure Measures Add Newer Meds Updated ACC/AHA Heart Failure Measures Add Newer Meds
Safety measures for lab monitoring of mineralocorticoid receptor agonist therapy, performance measures for sacubitril/valsartan, and cardiac resynchronization therapy are among the updates.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 3, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
How Is Cardiac Resynchronization Therapy Done?
Title: How Is Cardiac Resynchronization Therapy Done?Category: Procedures and TestsCreated: 4/22/2020 12:00:00 AMLast Editorial Review: 4/22/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 22, 2020 Category: Cardiology Source Type: news
Abbott Continues to Show Heart with ‘Breakthrough’ Announcement
Abbott Laboratories continues to extend its list of milestones in the cardiovascular space. The Abbott Park, IL-based company has now won Breakthrough Device Designation from FDA for the in-development Fully Implantable Left Ventricular Assist System (FILVAS).
FILVAS builds on the HeartMate 3 Left Ventricular Assist Device (LVAD). The technology was inherited by St. Jude Medical when it was acquired by Abbott. St. Jude inherited Heartmate 3 after it acquiredThoratec for $3.4 billion.
Kevin Bourque, Divisional Vice President of Research & Development for Abbott’s Mechanical Circulatory Support portfo...
Source: MDDI - February 4, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news
ICDs Have Come a Long Way in 40 Years
Michel Mirowski and his colleagues gave the field of implantable cardioverter-defibrillators (ICDs) a pretty good start, but what's more impressive is how far the technology has advanced since that first human ICD implant in February 1980. In the past 40 years we've seen ICDs become dramatically smaller, longer lasting, more capable, more personalized, subcutaneous (non-transvenous), and even MRI-firendly. And that's not to mention the advanced data connectivity and monitoring capabilities that the latest technologies offer. So without further ado, let's take a look at the current ICD landscape and the companie...
Source: MDDI - February 4, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news
Recall of Pacemaker in Nov. 2015 Was Delayed Unnecessarily
FRIDAY, Dec. 27, 2019 -- Recall of a cardiac resynchronization therapy pacemaker, which occurred in November 2015, was delayed unnecessarily, according to a report published online Dec. 20 in JAMA Internal Medicine.
Jay Sengupta, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2019 Category: Pharmaceuticals Source Type: news
Biomarkers to Predict the Response to CRT Biomarkers to Predict the Response to CRT
This article reviews the current evidence on promising biomarkers for predicting response to cardiac resynchronization therapy. Are any sufficiently reliable and sensitive?Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 28, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
(Massachusetts General Hospital) Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2019 Category: Cancer & Oncology Source Type: news
Cardiac Resynchronization Therapy Benefits Cancer Survivors with Heart Failure
A pacemaker-like device restored heart function in a group of cancer survivors — mostly women with breast cancer — who had suffered from heart failure as a result of chemotherapy, a study in the Journal of the American Medical Association (JAMA) reports. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 13, 2019 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Cardiac resynchronization therapy benefits cancer survivors with heart failure
(University of Rochester Medical Center) A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association (JAMA) reports. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2019 Category: International Medicine & Public Health Source Type: news
STOP-CRT: Maybe Stop Some HF Meds if CRT Restores Heart Function STOP-CRT: Maybe Stop Some HF Meds if CRT Restores Heart Function
It ' s only one study, but some highly selected patients might improve on cardiac resynchronization therapy such that RAAS inhibitors and beta blockers are no longer indicated, a researcher says.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 23, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
Cardiac'Shrinkage' on Sacubitril/Valsartan May Rival CRT in HF Cardiac'Shrinkage' on Sacubitril/Valsartan May Rival CRT in HF
LV volumes fell and LVEF rose, often 10 points or more, after a year on the ARNI. That approaches gains on cardiac resynchronization therapy,"the reverse-remodeling champion," a researcher notes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 11, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
New Data Presented at ESC Congress 2019 Supports ICD Use
This study investigated the association between ICD use and all-cause mortality in a contemporary reduced ejection fraction (HFrEF) cohort with a focus on subgroups. The study population was compiled from patients in the Swedish Heart Failure Registry (SwedeHF) fulfilling ESC criteria for primary prevention ICD use. Propensity score matching was used to account for differences at baseline.
In a release principal investigator Dr. Benedikt Schrage of the Karolinska Institute in Stockholm, Sweden said: “Most randomized trials on ICD use for primary prevention of sudden cardiac death in HFrEF enrolled patient...
Source: MDDI - September 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO
SUNNYVALE, Calif., Aug. 27, 2019 -- (Healthcare Sales & Marketing Network) -- EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of it... Devices, Cardiology, Venture Capital, Personnel EBR Systems, cardiac pacing, Cardiac Resynchronization Therapy, WISE CRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 27, 2019 Category: Pharmaceuticals Source Type: news
Some Heart Failure Patients May Benefit From CRT Defibrillator
THURSDAY, June 20, 2019 -- Cardiac resynchronization therapy with defibrillator (CRT-D) implantation is associated with better outcomes than an implantable cardioverter-defibrillator (ICD) for patients with nonspecific intraventricular conduction... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2019 Category: Pharmaceuticals Source Type: news
